Leap Therapeutics, Inc. (LPTX)

Market Cap	18.40M
Revenue (ttm)	n/a
Net Income (ttm)	-64.82M
Shares Out	38.32M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,251
Open	0.485
Previous Close	0.483
Day's Range	0.475 - 0.490
52-Week Range	0.473 - 4.790
Beta	0.14
Analysts	Buy
Price Target	8.50 (+1,670.1%)
Earnings Date	Mar 17, 2025

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: LPTX
• Website: https://www.leaptx.com

Analyst Forecast

According to 3 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 1,670.10% from the latest price.

Price Target

$8.5

(1,670.10% upside)

Analyst Consensus: Buy